Sometimes a stock drops for reasons that have nothing to do with the company itself. That seems to be the case with Eli Lilly & Co. (LLY) on Tuesday, as shares slipped about 2% in a broad risk-off session that hit healthcare stocks particularly hard.

The Nasdaq was down 0.29%, the S&P 500 fell 0.43%, and the Dow Jones dropped 1.05%. But healthcare was the weakest of the 11 S&P 500 sectors, down 1.7%. The market's advance-decline ratio stood at 0.8, meaning more stocks fell than rose.

So what's spooking healthcare investors? A big part of the story is biotech. Novartis AG (NVS) saw its stock plunge after its Phase 3 HARBOR trial for del-desiran failed to meet its primary endpoint. That's on top of another Phase 3 failure for its cardiovascular drug pelacarsen. These setbacks aren't just bad news for Novartis; they're dragging down partners like Ionis Pharmaceuticals Inc. (IONS) and Royalty Pharma plc (RPRX), which have financial ties to pelacarsen. When biotech stumbles, the whole sector feels it.

Technical Analysis: Long-Term Bull, Short-Term Bear

If you zoom out, Lilly's chart still looks pretty healthy. The stock is trading 1.5% above its 100-day simple moving average and 5.9% above its 200-day SMA. The 50-day SMA is also above the 200-day SMA, which is a classic bullish signal.

But the near-term picture is less rosy. Lilly is now 5.9% below its 20-day SMA and 5.3% below its 50-day SMA. Momentum indicators are also turning bearish: the MACD is below its signal line, and the histogram is negative. In plain English, buying momentum has weakened.

Here are the levels to watch: resistance sits near $1,232, while support is around $1,109, close to the 100-day SMA. If the stock breaks below that support, things could get interesting.

Sector Performance: Healthcare's Rough Day

Lilly is down 2.03%, which is actually a bit worse than the Health Care Select Sector SPDR Fund (XLV), which is off 1.71%. Healthcare is the worst-performing sector today, but that's a recent blip. Over the past 90 days, the sector is still up 10.17%. For context, Energy is up 1.74% today, and Utilities has gained 0.88%.

Analyst Outlook: Still Bullish, But Watch the Valuation

Despite the recent weakness, Wall Street remains firmly bullish on Lilly. The stock carries a Buy consensus rating with an average price forecast of $1,347.13. That's about 19% above the current price.

Recent analyst actions have been positive too. Truist Securities maintained a Buy rating and raised its price target to $1,376 on Aug. 7. Wells Fargo maintained an Overweight rating and bumped its target to $1,330 on Aug. 6. Cantor Fitzgerald also maintained an Overweight rating and lifted its target to $1,410 on Aug. 6.

But here's the catch: the stock trades at a price-to-earnings ratio of 38.6. That's a premium valuation by any measure. It reflects high expectations for growth, but it also means the stock has less room for error. If the market gets jittery, high-multiple stocks like Lilly can get hit harder.

Fundamentals: Strong Growth, Weak Value

MarketDash's Edge scorecard paints a clear picture. Lilly scores 98.97 on Growth, 96.72 on Quality, and 83.12 on Momentum. Those are stellar numbers. But its Value score is just 1.54. That's a huge disconnect.

What does that mean? Lilly is a high-quality, fast-growing company, but you're paying a hefty price for that. The combination of strong growth and poor value suggests the stock could be more vulnerable during market pullbacks. When investors get risk-averse, they often rotate out of expensive stocks first.

ETF Exposure: The Hidden Hand

It's also worth noting that Lilly is a heavyweight in several healthcare ETFs. The Simplify Health Care ETF (PINK) has a 9.93% weighting in Lilly. The Polen Focus Growth ETF (PCLG) has a 7.72% weighting, and the First Trust Nasdaq Pharmaceuticals ETF (FTXH) has a 7.38% weighting.

That means when money flows into or out of these ETFs, it can create significant buying or selling pressure on Lilly shares. So even if nothing changes at the company itself, ETF flows can move the stock.

Price Action

At the time of publication Tuesday, Eli Lilly shares were down 1.94% at $1,127.04, according to market data.

So, what's the takeaway? Lilly's drop today is more about the sector than the company. The biotech trial failures are creating a risk-off mood in healthcare, and Lilly is getting caught in the crossfire. The long-term story remains intact, but the short-term technicals and rich valuation suggest investors should keep an eye on support levels. If the broader market stabilizes, Lilly could bounce back quickly. If not, $1,109 is the line in the sand.